

EXHIBIT 2

Foster, Adam

From: Udapi, Guruprasad <Guruprasad.Udapi@fda.hhs.gov>
Sent: Tuesday, May 31, 2022 12:52 PM
To: Wisner, R. Brent
Cc: Foster, Adam
Subject: RE: [EXTERNAL] Re: FOIA request 2022-2942 status inquiry

Good afternoon Mr. Wisner,

This email is sent to memorialize our conversation on 5/27/22 regarding the above referenced FOIA request. Per our conversation, FOIA Requests for email correspondence are categorized as Complex Track Requests. Complex Track FOIA Requests are processed in the order in which they are received. Currently, your request is #801 in the processing queue. Therefore, the minimum estimated processing timeframe is 24 months. CDER will notify you when the request is approaching the top of the processing queue. Thank you for taking the time to discuss the matter with me. Feel free to contact me should you have any questions regarding this matter.

Guruprasad Udapi
Branch Chief
Division of Information Disclosure Policy, FOIA Branch
Office of Regulatory Policy, CDER
Work: (301) 796-2660
Cell: (240) 702-3926

From: Udapi, Guruprasad
Sent: Thursday, May 26, 2022 1:50 PM
To: 'Wisner, R. Brent' <rbwisner@baumhedlundlaw.com>; Coleman, Rochelle A <Rochelle.Coleman@fda.hhs.gov>
Cc: Foster, Adam <afoster@baumhedlundlaw.com>
Subject: RE: [EXTERNAL] Re: FOIA request 2022-2942 status inquiry

Yes, I will be available at 11am tomorrow.

Guruprasad Udapi
Branch Chief
Division of Information Disclosure Policy, FOIA Branch
Office of Regulatory Policy, CDER
Work: (301) 796-2660
Cell: (240) 702-3926

From: Wisner, R. Brent <rbwisner@baumhedlundlaw.com>
Sent: Thursday, May 26, 2022 1:33 PM
To: Udapi, Guruprasad <Guruprasad.Udapi@fda.hhs.gov>; Coleman, Rochelle A <Rochelle.Coleman@fda.hhs.gov>
Cc: Foster, Adam <afoster@baumhedlundlaw.com>
Subject: Re: [EXTERNAL] Re: FOIA request 2022-2942 status inquiry

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you for getting back to me. I am currently traveling and will be on a plane until 4:00 pm PT. Are you free to speak tomorrow? I propose 11 am ET.

R. Brent Wisner
Vice President, Senior Shareholder
Baum Hedlund
(Sent from iPhone)

From: Udapi, Guruprasad <Guruprasad.Udapi@fda.hhs.gov>
Sent: Thursday, May 26, 2022 12:29:15 PM
To: Wisner, R. Brent <rbwisner@baumhedlundlaw.com>; Coleman, Rochelle A <Rochelle.Coleman@fda.hhs.gov>
Cc: Foster, Adam <afoster@baumhedlundlaw.com>
Subject: RE: [EXTERNAL] Re: FOIA request 2022-2942 status inquiry

Good afternoon Mr. Wisner,

I attempted to reach you on the phone number listed below and left you a VM. I will be available between 2-2:30 pm and after 3:30pm today to discuss the FOIA Request. You may reach me at 240-702-3926. Thank you.

Guruprasad Udapi
Branch Chief
Division of Information Disclosure Policy, FOIA Branch
Office of Regulatory Policy, CDER
Work: (301) 796-2660
Cell: (240) 702-3926

From: Wisner, R. Brent <rbwisner@baumhedlundlaw.com>
Sent: Thursday, May 26, 2022 1:06 PM
To: Coleman, Rochelle A <Rochelle.Coleman@fda.hhs.gov>
Cc: Udapi, Guruprasad <Guruprasad.Udapi@fda.hhs.gov>; Foster, Adam <afoster@baumhedlundlaw.com>
Subject: [EXTERNAL] Re: FOIA request 2022-2942 status inquiry

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I am once again following up the below FOIA request. Please respond.

R. Brent Wisner
Vice President, Senior Shareholder
Baum Hedlund
(Sent from iPhone)

From: Wisner, R. Brent
Sent: Friday, May 20, 2022 2:37:04 PM
To: Coleman, Rochelle A <Rochelle.Coleman@fda.hhs.gov>
Cc: Udapi, Guruprasad <Guruprasad.Udapi@fda.hhs.gov>; Foster, Adam <afoster@baumhedlundlaw.com>
Subject: RE: FOIA request 2022-2942 status inquiry

Guruprasad,

My name is Brent Wisner. I am attorney in California. I have copied another attorney from my firm to this email. Please copy Mr. Foster on all future correspondence as well.

We served a FOIA request on April 22, 2022. The FOIA control number is 2022-2942.

Based on my calculations, and pursuant to statute, we should have received a response to the FOIA request, with accompanying documents, by today. Hence, this email. I was wondering if I could get a status update on (1) the FDA's response to the request, and the (2) anticipated date of document production. We are eager to get this resolved.

I appreciate your prompt attention and response to this.

Best,

R. Brent Wisner

Vice President | Senior Shareholder

☎ (310) 207-3233

🌐 baumhedlund.com

📍 10940 Wilshire Blvd, Suite 1600
Los Angeles, CA 90024



CONFIDENTIALITY NOTICE – This electronic mail message may contain confidential information belonging to the sender which is protected by the attorney-client and/or work product privilege. The information is intended only for the use of the individual(s) or entity(ies) named above. If you are not the intended recipient, you are notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this transmission in error, please purge the received information from your system and immediately notify the sender by telephone and by return e-mail. Thank you. IRS DISCLAIMER: Communications from our firm may contain or incorporate federal tax advice. Under recently promulgated US Internal Revenue Service standards (Circular 230), we are required to inform you that only formal, written tax opinions meeting the requirements of Circular 230 may be relied upon by taxpayers for the purpose of avoiding tax-related penalties. Accordingly, this communication is not intended or written to be used, and it cannot be used, for the purpose of avoiding tax-related penalties under the Internal Revenue Code.

From: Coleman, Rochelle A <Rochelle.Coleman@fda.hhs.gov>
Sent: Friday, May 20, 2022 12:20 PM
To: Wisner, R. Brent <rbwisner@baumhedlundlaw.com>
Cc: Udapi, Guruprasad <Guruprasad.Udapi@fda.hhs.gov>
Subject: FOIA request 2022-2942 status inquiry

Your request has been assigned to the Center for Drug Evaluation and Research Guruprasad.udapi@fda.hhas.gov. Any questions regarding this request can be addressed with that office.

Thank you.